Solara Active Pharma Sciences (NSE:SOLARA) pulls back 17% this week, but still delivers shareholders decent 10% CAGR over 3 years

Solara Active Pharma Sciences Limited (NSE:SOLARA) shareholders might be concerned after seeing the share price drop 17% in the last week. On the other hand the share price is higher than it was three years ago. Arguably you'd have been better off buying an index fund, because the gain of 24% in three years isn't amazing.

Although Solara Active Pharma Sciences has shed ₹4.6b from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

We don't think that Solara Active Pharma Sciences' modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

Over the last three years Solara Active Pharma Sciences has grown its revenue at 0.6% annually. That's not a very high growth rate considering it doesn't make profits. It's probably fair to say that the modest growth is reflected in the modest share price gain of 7% per year. A closer look at the revenue and profit trends could uncover help us understand if the company will be profitable in the future.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

We know that Solara Active Pharma Sciences has improved its bottom line lately, but what does the future have in store? So it makes a lot of sense to check out what analysts think Solara Active Pharma Sciences will earn in the future (free profit forecasts).

What About The Total Shareholder Return (TSR)?

Investors should note that there's a difference between Solara Active Pharma Sciences' total shareholder return (TSR) and its share price change, which we've covered above. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Solara Active Pharma Sciences' TSR of 34% for the 3 years exceeded its share price return, because it has paid dividends.

A Different Perspective

While the broader market gained around 3.7% in the last year, Solara Active Pharma Sciences shareholders lost 1.4%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 2%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Solara Active Pharma Sciences .

Of course Solara Active Pharma Sciences may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Indian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.